Last updated: September 4, 2026
Lumasiran sodium, marketed by Alnylam Pharmaceuticals as Oxlumo, is an RNA interference treatment for primary hyperoxaluria type 1, or PH1. The product has a high-value orphan-drug model, limited direct competition, and a commercial trajectory driven more by diagnosis and treatment-center penetration than by broad patient volume. Revenue has expanded steadily since the 2020 U.S. launch, but the product remains a small contributor to Alnylam’s overall sales compared with newer RNAi products such as Amvuttra.
What is lumasiran sodium and how does Oxlumo work?
Lumasiran sodium is a chemically synthesized small interfering RNA, or siRNA, administered by subcutaneous injection. Oxlumo targets hydroxyacid oxidase 1, or HAO1, messenger RNA in the liver. HAO1 encodes glycolate oxidase, an enzyme involved in the production of glyoxylate. Reducing HAO1 expression lowers hepatic oxalate production.
| Attribute |
Detail |
| Active ingredient |
Lumasiran sodium |
| Brand |
Oxlumo |
| Developer and marketer |
Alnylam Pharmaceuticals |
| Modality |
GalNAc-conjugated siRNA |
| Primary disease |
Primary hyperoxaluria type 1 |
| FDA application |
NDA 214103 |
| U.S. approval |
November 22, 2020 |
| Administration |
Subcutaneous injection |
| Initial regimen |
Three monthly loading doses |
| Maintenance regimen |
Every three months |
| Commercial category |
Ultra-rare disease, specialty pharmaceutical |
| Regulatory designation |
Orphan-drug product |
The FDA approved Oxlumo for adults and children with PH1, without restricting use by renal function. The treatment is intended to reduce urinary oxalate and the risk of kidney-stone formation, nephrocalcinosis and progressive kidney damage (U.S. Food and Drug Administration, 2020).
How large is the lumasiran sodium market?
The addressable market is small in patient count but large in revenue per treated patient. PH1 is an ultra-rare inherited disorder. Published estimates generally place the global PH1 population in the range of several thousand diagnosed and undiagnosed patients, with substantial geographic variation in testing and case ascertainment.
The commercial market is shaped by five factors:
- Low disease prevalence.
- Underdiagnosis and delayed genetic confirmation.
- High annual treatment cost.
- Concentration of care in specialist nephrology and metabolic centers.
- The need to treat patients before irreversible renal damage develops.
The most important market-expansion opportunity is diagnosis. Patients with recurrent calcium oxalate kidney stones, nephrocalcinosis, unexplained renal failure or early kidney transplantation may not receive PH1 testing promptly. Alnylam’s commercial strategy has therefore emphasized genetic testing, physician education and referral pathways.
Oxlumo does not require a large primary-care sales force. Its commercial model depends on a smaller network of metabolic disease, pediatric nephrology, adult nephrology and transplant specialists.
What is the financial trajectory for Oxlumo?
Oxlumo revenue has followed a typical orphan-drug launch curve: low initial sales during market introduction, followed by growth from diagnosis, geographic expansion and conversion of eligible patients to long-term maintenance treatment.
Alnylam reports Oxlumo revenue within its product portfolio disclosures. Public company filings show that annual revenue moved from launch-stage levels in 2021 to a roughly $100 million annual scale by 2023.
| Fiscal period |
Commercial phase |
Reported direction |
| 2020 |
U.S. launch |
Initial approval and market access |
| 2021 |
Early launch |
Limited revenue while treatment centers and diagnosis pathways developed |
| 2022 |
Expansion |
Revenue increased as patient identification and international access improved |
| 2023 |
Established rare-disease product |
Annual revenue reached approximately the $100 million range |
| 2024 onward |
Maturity and penetration |
Growth depends on diagnosed-patient capture, pediatric uptake and international reimbursement |
Oxlumo’s revenue is strategically important because it is recurring and treatment is chronic. The product is administered every three months after loading, creating repeat demand rather than one-time treatment revenue.
Its absolute contribution to Alnylam is smaller than that of Amvuttra, which has a substantially larger addressable population in transthyretin-mediated amyloidosis. Oxlumo is therefore unlikely to become Alnylam’s main growth engine, but it provides a differentiated rare-disease revenue stream with limited direct competition.
The major financial variables are:
- Number of diagnosed PH1 patients.
- Speed of genetic confirmation.
- Insurance approval rates.
- U.S. and European reimbursement.
- Persistence on quarterly maintenance dosing.
- Pediatric diagnosis and treatment.
- Expansion into markets with limited PH1 testing.
- Potential future competition from RNAi or enzyme-targeting therapies.
Alnylam has not publicly disclosed Oxlumo profitability as a standalone product. Gross margin is likely supported by the economics of an RNAi product, but commercial infrastructure, patient identification, reimbursement support and international launch expenses reduce product-level operating leverage during the expansion phase.
What is the price and reimbursement model for lumasiran?
Oxlumo is priced as an ultra-orphan therapy. The effective annual cost varies by patient weight, loading requirements, contractual discounts and payer arrangements. The first year is more expensive because it includes three monthly loading doses, while subsequent years use quarterly maintenance dosing.
The reimbursement environment differs by jurisdiction:
- In the United States, coverage is primarily determined by commercial insurers, Medicaid programs and specialty pharmacy or medical-benefit arrangements.
- In Europe, national or regional health technology assessment and reimbursement decisions control access.
- In countries with centralized rare-disease funding, treatment may be restricted to designated centers.
- In lower-income markets, genetic testing and reimbursement are major barriers to uptake.
Because PH1 can cause irreversible kidney damage, payers may view early treatment as a means of reducing dialysis, transplantation and hospitalization costs. The economic case is strongest for patients at risk of renal decline and for children with prolonged lifetime exposure.
High price remains a commercial risk. Payers may require molecular confirmation, documented disease severity, specialist prescribing or prior authorization. These controls can delay initiation and reduce near-term prescription conversion.
What FDA regulatory exclusivity protects Oxlumo?
Oxlumo received U.S. orphan-drug exclusivity upon approval for PH1. The statutory orphan exclusivity period is seven years from approval, subject to the terms of the Orphan Drug Act. On that basis, the principal U.S. orphan exclusivity period runs through November 2027.
The product also benefits from the practical difficulty of developing a competing therapy for a very small population. Orphan exclusivity does not prevent all competing products. A different drug may obtain approval for the same disease if it demonstrates clinical superiority, and separate products may enter through distinct regulatory strategies.
The FDA approval was supported by the ILLUMINATE clinical development program. The pivotal evidence showed substantial reductions in urinary oxalate, with pediatric and adult data supporting the broad labeled population (U.S. Food and Drug Administration, 2020; Alnylam Pharmaceuticals, 2023).
What patents protect lumasiran sodium and Oxlumo?
The Oxlumo patent position is based on several potential layers:
- Lumasiran composition and sequence claims.
- Conjugate and delivery-system claims.
- Pharmaceutical-composition claims.
- Methods of reducing oxalate production.
- Methods of treating PH1.
- Manufacturing and formulation claims.
The commercial value of the estate depends on the scope and enforceability of claims covering the specific siRNA sequence, chemical modifications, GalNAc conjugation and therapeutic use. RNAi products can have patent estates that extend beyond the regulatory exclusivity period, but the practical protection depends on claim construction, validity challenges and whether a competing product uses a non-infringing sequence or delivery architecture.
Oxlumo is regulated through an NDA rather than the biologics license application pathway used for protein biologics. The Orange Book is therefore the primary FDA reference for any listed patents and regulatory exclusivities associated with the approved product. Patent expiry should be assessed patent-by-patent rather than through a single assumed product date because formulation, method-of-use and composition claims can expire at different times (U.S. Food and Drug Administration, 2024).
Are there formulation and manufacturing barriers?
Yes. The product’s barriers extend beyond the active siRNA sequence.
Manufacturing requires:
- Oligonucleotide synthesis at commercial scale.
- Controlled conjugation to the GalNAc ligand.
- Purification and impurity control.
- Sterile injectable production.
- Consistent particle and chemical quality.
- Stability control for a refrigerated injectable product.
A generic or follow-on competitor would need to establish pharmaceutical equivalence and demonstrate quality, analytical comparability and regulatory acceptability. For complex oligonucleotides, manufacturing consistency can be more difficult than for conventional small-molecule tablets.
These barriers do not guarantee long-term market protection. A competitor may design a different siRNA sequence, use an alternative conjugate or pursue a new molecular entity rather than an abbreviated generic pathway.
When does lumasiran lose exclusivity?
The most visible U.S. regulatory protection is the seven-year orphan-drug exclusivity period ending in November 2027. Patent protection may extend beyond that date, depending on the relevant issued patents, patent-term adjustment, patent-term extension and claim scope.
A generic launch immediately after orphan exclusivity is not automatic. Entry would require:
- An acceptable FDA regulatory pathway.
- A non-infringement or invalidity position against relevant patents.
- Sufficient manufacturing capacity.
- Payer access.
- Commercial economics that justify entering a very small market.
In Europe, orphan medicinal-product market exclusivity generally runs for ten years from authorization, with a potential extension to twelve years if pediatric requirements are satisfied. The European position must be evaluated separately from the U.S. position because approval dates, supplementary protection certificates and national enforcement differ.
Which companies are challenging Oxlumo?
No direct generic or biosimilar competitor had displaced Oxlumo in the principal markets through the established launch period. The most relevant competitive threat is pipeline competition rather than an immediate abbreviated product.
Potential competitors include:
- Nedosiran, an RNAi therapy developed for primary hyperoxaluria.
- Other HAO1- or glycolate-oxidase-targeting approaches.
- Enzyme replacement or substrate-reduction therapies.
- Improved dialysis, transplantation and supportive management.
- Future gene-editing or gene-replacement strategies.
Nedosiran is strategically important because it uses RNAi to target lactate dehydrogenase, or LDHA, and has been studied across PH1 and other forms of primary hyperoxaluria. Its commercial impact would depend on approval, label breadth, dosing frequency, clinical differentiation and manufacturing economics.
A competitor with broader PH coverage could challenge Oxlumo even if it does not match lumasiran’s exact mechanism. A therapy that treats PH2 or offers an easier administration schedule could expand the market while reducing Oxlumo’s share of PH1 treatment.
How strong is the lumasiran patent and commercial estate?
The estate is commercially strong in the near term but less secure as a long-term monopoly than a conventional product with broad small-molecule composition claims.
Strengths include:
- First approved therapy specifically targeting the metabolic source of oxalate in PH1.
- Orphan-drug exclusivity.
- Specialized RNAi chemistry and GalNAc delivery.
- Complex manufacturing requirements.
- A concentrated prescriber and diagnostic network.
- Clinical use in both adults and children.
- Limited current direct competition.
Risks include:
- Very small patient population.
- Potential design-around using alternative siRNA sequences.
- Regulatory uncertainty for follow-on oligonucleotide products.
- Reimbursement pressure on a high-cost chronic therapy.
- Competition from differentiated RNAi mechanisms.
- Dependence on genetic testing and specialist diagnosis.
The estate is therefore strongest as an integrated regulatory, clinical, manufacturing and commercial position. Patent protection alone is less likely to determine market duration than the combined effect of orphan status, clinical adoption and the complexity of developing a competing therapy.
What licensing deals affect lumasiran sodium?
Lumasiran is an Alnylam-originated product based on the company’s RNAi platform. No major third-party licensing transaction is required to explain the product’s commercial position. The relevant strategic asset is Alnylam’s proprietary GalNAc-siRNA platform, which supports multiple products in the company’s portfolio.
Alnylam’s broader collaborations and platform licenses may affect RNAi technology economics, but they should not be treated as product-specific Oxlumo revenue-sharing arrangements unless expressly identified in company filings.
What generic launch risks exist for Oxlumo?
A plausible generic or follow-on launch would face several barriers:
| Barrier |
Commercial effect |
| Small patient population |
Limits revenue available to a new entrant |
| Patent litigation |
Can delay launch and increase development cost |
| Complex oligonucleotide manufacturing |
Raises capital and quality-control requirements |
| Specialist prescribing |
Requires access to a concentrated treatment network |
| Genetic confirmation |
Slows patient conversion |
| Payer restrictions |
Can delay reimbursement |
| Sequence or conjugate design-around |
May require a full clinical-development program |
| Pediatric use |
Increases evidence requirements |
A Paragraph IV challenge is possible after an ANDA applicant identifies relevant Orange Book patents, but the commercial incentive may be weaker than for a mass-market medicine. The likely entry scenario is not a large generic wave. It is a single specialized competitor, a clinically differentiated RNAi therapy or a new product with broader hyperoxaluria coverage.
How does Oxlumo compare with competing rare-disease therapies?
Oxlumo has several advantages over supportive care and conventional interventions:
| Factor |
Oxlumo |
Supportive care or transplantation |
| Disease modification |
Reduces hepatic oxalate production |
Does not directly suppress production |
| Administration |
Quarterly maintenance injection |
Repeated medical management or surgery |
| Patient eligibility |
PH1 across age groups |
Depends on renal status and clinical severity |
| Revenue model |
Chronic specialty treatment |
Episodic or procedure-linked costs |
| Commercial risk |
High price and small population |
High long-term healthcare burden |
| Competitive exposure |
Future RNAi and metabolic therapies |
Standard-of-care persistence |
Compared with a potential competitor such as nedosiran, the key comparison points will be disease coverage, dosing frequency, renal outcomes, pediatric evidence, safety, reimbursement and patent duration. A competitor that treats more than PH1 could command greater prescriber attention even if Oxlumo remains effective in its approved population.
What is the outlook for lumasiran sodium revenue?
The base-case outlook is continued moderate growth rather than explosive expansion. The product can grow through diagnosis of untreated PH1, pediatric treatment, international reimbursement and long-term persistence. Revenue is likely to plateau once the diagnosed and reimbursed PH1 population is substantially penetrated.
The principal upside scenario involves broader genetic testing and earlier treatment before renal failure. The downside scenario involves payer restrictions, weak diagnosis rates, competing RNAi approval or patent-driven entry after regulatory exclusivity.
For Alnylam, Oxlumo is best viewed as a durable niche product. Its strategic value exceeds its revenue share because it validates the company’s rare-disease RNAi platform and creates a specialist commercial infrastructure that can support related products.
Key Takeaways
- Lumasiran sodium is marketed as Oxlumo for PH1.
- FDA approval occurred on November 22, 2020, under NDA 214103.
- The product uses GalNAc-conjugated siRNA to reduce hepatic oxalate production.
- Revenue increased from launch-stage levels to approximately $100 million annually by 2023.
- Growth depends on diagnosis, genetic testing, reimbursement and pediatric penetration.
- U.S. orphan-drug exclusivity runs through November 2027.
- Patent protection may extend beyond orphan exclusivity, but expiry must be evaluated claim by claim.
- There was no established generic or biosimilar replacement during the main launch period.
- Nedosiran and other RNAi or metabolic therapies represent the principal competitive risks.
- Manufacturing complexity and specialist distribution strengthen the commercial barrier to entry.
- Oxlumo is a durable but relatively small contributor to Alnylam’s total revenue base.
FAQs About Lumasiran Sodium and Oxlumo
Is lumasiran sodium a biologic?
No. Lumasiran sodium is a chemically synthesized siRNA drug regulated through an FDA NDA. It is not a conventional protein biologic regulated under a BLA.
Is Oxlumo a cure for primary hyperoxaluria type 1?
No. Oxlumo reduces oxalate production and disease burden but does not correct the underlying genetic mutation. Treatment is generally chronic.
Can Oxlumo be replaced by kidney transplantation?
Transplantation may be required for advanced disease, but it does not function as a direct commercial substitute for early pharmacologic treatment. Lumasiran is intended to reduce oxalate production and preserve renal function.
What is the main commercial threat to Oxlumo?
The main threat is a competing therapy with broader hyperoxaluria coverage, superior dosing convenience or stronger renal-outcome data. A traditional generic challenge is less likely to be the only competitive pathway.
Does lumasiran have biosimilar competition?
No conventional biosimilar pathway applies because lumasiran is a synthetic oligonucleotide rather than a protein biologic. Follow-on competition would more likely involve an abbreviated oligonucleotide product or a separately developed RNAi therapy.
References
-
Alnylam Pharmaceuticals, Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
Alnylam Pharmaceuticals, Inc. (2023). Oxlumo prescribing information. Alnylam Pharmaceuticals.
-
European Medicines Agency. (2020). Oxlumo: EPAR - product information. European Union.
-
U.S. Food and Drug Administration. (2020, November 22). FDA approves first treatment for primary hyperoxaluria type 1. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Orphan Drug Act and related regulatory provisions. U.S. Department of Health and Human Services.
